ALK and non-small cell lung carcinoma: The development of the ALK TKI in NSCLC patients, beginning with crizotinib, the first molecule approved and followed by second and third-generation inhibitors (ceritinib, alectinib, brigatinib, and lorlatinib) has provided an increased progression-free survival (PFS) and overall survival (OS) in comparison with chemotherapy [5,6].